The Latest Breaking News from Perrigo

FDA panel backs over-the-counter birth control pill

Federal health advisers are recommending that a decades-old birth control pill be sold without a prescription

The Independent UK · May 10, 2023

The FDA considers first birth control pill without a prescription

The Food and Drug Administration is weighing whether to allow a birth control pill to be sold over the counter for the first time. An advisory committee opens a two-day hearing Tuesday.

WEKU · May 9, 2023

FDA weighing 1st over-the-counter birth control pill

U.S. health regulators are weighing the first-ever request to make a birth control pill available without a prescription

The Independent UK · May 5, 2023

FDA delays key advisory committee meeting on OTC birth control - Roll Call

The delay comes as Democrats agitate for increased access to birth control in the wake of the Supreme Court decision overturning Roe v. Wade.

Roll Call · Oct 26, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022

Upgrades

Benzinga · Sep 6, 2022

This $5B Pharmaceutical Could Benefit From Over-The-Counter Contraceptives And Plan B Alternatives

The ruling by the U.S. Supreme Court to overturn Roe v. Wade and leave the decision of abortion to the states has been a big topic over the last few days. An analyst singles out a pharmaceutical company that could benefit from increased purchases of over-the-counter contraceptives.

Benzinga · Jun 27, 2022

Shortages mean higher profit margins for baby formula makers

While shortages have tormented parents, baby formula makers are recording higher profit margins.

Axios · Jun 17, 2022

Is Perrigo a Buy After Reporting Q1 Earnings?

The shares of leading baby formula maker Perrigo Company (PRGO) have been soaring in price of late amid a nationwide baby formula shortage. So, because the crisis is expected to continue through the coming months, will PRGO be able to maintain this momentum in the near term? Read more to…

StockNews.com · May 20, 2022

Perrigo Shares Pop On Raised FY22 Guidance Surpassing Consensus Estimates

Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion. The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after competitor recall. Adjusted EPS decreased 34% to $0.33, as higher sales…

Benzinga · May 11, 2022

Perrigo Clocks 5% Sales Growth In Q4, Bottom-Line Surpass Expectation

Perrigo Company plc (NYSE: PRGO) 

Benzinga · Mar 1, 2022